The global hospital-acquired disease testing market reached a value of US$ 1,021 Million in 2019. Hospital acquired infections (HAIs) or nosocomial infections are diseases that are acquired in hospitals and medical clinics. Nosocomial means, infections or diseases originating in a hospital. A person can get such diseases even in the vicinity of a nursing home, rehabilitation center, hospital or any other clinical surroundings. Most people get HAIs when they are in intensive care units (ICUs) and the emergency rooms (ERs). Generally, the incubation period of these diseases vary between 48 hours to 4 days after the individual gets admitted. A major reason behind the cause of hospital acquired diseases is the lack of proper hygiene in the hospital settings by the internal staff. Another reason can be below-par maintenance, complacency by the hospital staff, and a rise in multi-drug resistant organisms (MDROs). Some of the most commonly occurring nosocomial infections include pneumonia, primary bloodstream infections, urinary tract infections, etc. In many cases, it has also been found that these nosocomial infections are sometimes traced to the patients’ own microbiome. It happens when the protective skin layer comes in contact with possible threats and causes infection to occur, especially after surgical operations.
The market for hospital acquired disease testing is currently exhibiting double digit growth rates. Catalyzed by rising population and modernization of the healthcare infrastructure, there has been a significant increase in the number of health care facilities across the globe. This has resulted in a rising incidence of HAIs, driving the demand of hospital acquired disease tests. Moreover, with advanced technologies and scientific innovations, various techniques are now available in the market for preventing, diagnosing, and monitoring HAIs such as microarrays, polymerase chain reaction (PCR), real time location systems (RTLSs), and solid phase hybridization. Techniques such as RTLS makes it easy to prevent HAIs from spreading in both patients and staff. Growing awareness of HAIs among patients and governments enacting regulations that penalize hospitals having a high incidence of HAIs are some of the other factors that are catalyzing the growth of the market. Looking forward, the market value is projected to reach US$ 2,527 Million by 2025, exhibiting a CAGR of around 16.3% during 2020-2025.
This report provides a deep insight into the global hospital-acquired disease testing market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the hospital-acquired disease testing market in any manner.
Key Questions Answered in This Report:
The global hospital acquired disease testing market was worth US$ 1,021 Million in 2019.
The outbreak of the coronavirus disease (COVID-19) has positively impacted the market as many individuals are acquiring the infection from infected patients while visiting hospitals and medical clinics.
The rising incidences of hospital-acquired infections (HAIs) and modernization of healthcare infrastructure represent the primary factors bolstering the market growth. Growing awareness of HAIs among patients and government regulations penalizing hospitals with a high incidence rate of HAIs are also positively impacting the market.
One of the major market trends is the development of various technologies to prevent, monitor and diagnose hospital-acquired infections, like microarrays, polymerase chain reaction (PCR), real-time location system (RTLSs), and solid-phase hybridization.
The global hospital acquired disease testing market is expected to reach US$ 2,527 Billion by 2025.
Based on the indication, urinary tract infection (UTI) currently dominates the market. Other major segments are surgical site infection (SSI), pneumonia, bloodstream infections and methicillin-resistant staphylococcus aureus (MRSA).
Region-wise, North America exhibits a clear dominance in the market. Other major regions include Europe, Asia Pacific, Middle East and Africa, and Latin America.
The leading players operating in the industry are Abbott Laboratories, Alere, Inc., Becton, Dickinson and Company, bioMerieux SA, F.Hoffmann-La Roche Ltd., Hologic, Inc., QIAGEN GmbH, Siemens Healthineers GmbH, Diatherix Eurofins, LLC., Meridian Bioscience, Inc., Thermo Fisher Scientific, Inc. (Life Technologies Corporation) and Cepheid, Inc.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-702-409-7331 )
( India: +91-120-433-0800 )
Drop us an email at